Kerry Wentworth is VP & Clinical +1 at ANTIGENICS INC /DE/ (AGEN). They have made 8 open-market trades across 3 companies since 2009, most recently 2026-06-23.
CIK 0001369453
1 open-market purchase totalling $90K since 2025, against 7 sales. Too few scored purchases to measure a record yet.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| NUVB | SELL · 10b5-1 | 2026-06-23 | 2026-06-24 | $6.02 | $379K | +0.9% | +14.6% | +8.7% |
| NUVB | SELL · 10b5-1 | 2026-04-17 | 2026-04-21 | $5.01 | $184K | -14.8% | -8.8% | +19.0% |
| NUVB | SELL · 10b5-1 | 2026-04-06 | 2026-04-08 | $4.52 | $904K | +15.6% | +8.1% | +28.0% |
| NUVB | BUY | 2025-06-16 | 2025-06-18 | $1.79 | $90K | +1.0% | +19.8% | +70.3% |
| FLXN | SELL | 2021-07-19 | 2021-07-20 | $6.45 | $25K | -13.2% | -35.6% | +36.3% |
| FLXN | SELL | 2021-01-05 | 2021-01-07 | $11.13 | $152K | -5.0% | +4.7% | -33.1% |
| FLXN | SELL · 10b5-1 | 2019-01-03 | 2019-01-04 | $12.36 | $8K | +1.4% | +6.5% | -5.4% |
| AGEN | SELL · 10b5-1 | 2014-02-26 | 2014-02-28 | $5.00 | $25K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL | 2011-12-27 | 2011-12-29 | $2.05 | $29K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL | 2011-12-21 | 2011-12-23 | $2.22 | $13K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL · 10b5-1 | 2010-10-26 | 2010-10-28 | $0.97 | $4K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL | 2010-09-14 | 2010-09-14 | $0.91 | $1K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL · 10b5-1 | 2010-07-26 | 2010-07-28 | $0.80 | $3K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL · 10b5-1 | 2010-04-26 | 2010-04-28 | $1.21 | $5K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL · 10b5-1 | 2010-01-20 | 2010-01-22 | $0.85 | $87K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL | 2009-09-11 | 2009-09-14 | $2.32 | $3K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL | 2009-07-15 | 2009-07-17 | $1.68 | $56K | -27.3% | -0.9% | -0.9% |
| AGEN | SELL · Routine | 2009-06-25 | 2009-06-29 | $1.97 | $49K | -27.3% | -0.9% | -0.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.